Is TXG a Buy? What to Consider in 2026
Short answer
The bull case for TXG (TXG) rests on Consumables-led recurring revenue: Even with instrument sales frozen, consumables grew about 13% year over year in Q1 2026 as the large installed base of Chromium and spatial instruments keeps ordering reagents. Revenue (TTM) is ~$639M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The biggest overhang is demand: U.S. Whether TXG is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
10x Genomics, Inc. (Nasdaq: TXG) builds instruments, reagents, and software for single-cell and spatial biology, the tools scientists use to read gene activity one cell at a time and map it across intact tissue. Its core franchises are Chromium (single-cell analysis), the Visium and Xenium spatial platforms, and the newly launched Atera in situ system (list price around $495,000, shipping in the second half of 2026). Revenue skews toward recurring consumables sold to academic labs, pharma and biotech research groups, and core genomics facilities, with instrument placements driving the razor-and-blade model over time. The investment picture is a category leader growing slowly through a rough patch. Trailing-twelve-month revenue is roughly $639M with the company still running a modest net loss, though gross margin has improved to about 70% and the balance sheet carries roughly $540M of cash and no debt. Full-year 2026 guidance of $600M to $625M implies only 0% to 4% growth after stripping out one-time patent-settlement revenue, reflecting a deep freeze in academic and biopharma capital-equipment budgets (instrument sales fell about 24% year over year in Q1). The stock (market cap roughly $5B, price-to-sales near 7x) is priced on the expectation that consumables growth and new platforms like Atera eventually reaccelerate the top line.
What's the case for buying TXG?
1. Consumables-led recurring revenue
Even with instrument sales frozen, consumables grew about 13% year over year in Q1 2026 as the large installed base of Chromium and spatial instruments keeps ordering reagents. This recurring, higher-margin revenue is the ballast that helped lift gross margin toward 70% and narrow losses. A growing installed base compounds this stream over time.
2. New platform launches (Atera and spatial)
10x launched the Atera in situ platform in April 2026, promising whole-transcriptome spatial analysis at single-cell resolution, with shipments starting in the second half of the year. Xenium and Visium continue to expand the spatial franchise. New instruments both seed future consumables pull-through and defend the company's technology leadership.
3. Market leadership and consolidation
10x is the recognized leader across single-cell and spatial biology, and the space has consolidated (former rival NanoString went through bankruptcy and is now Bruker Spatial). That created an opening to capture displaced customers. The company is also pushing single-cell technology toward clinical and diagnostic applications, a potential longer-term expansion beyond research.
4. Margin and cost discipline
Operating expenses fell about 15% year over year in Q1 2026 on lower legal, personnel, and marketing costs, and gross margin rose on fewer inventory write-downs and warranty charges. With roughly $540M of cash and no debt, the company has runway to fund launches while it works toward sustained profitability.
What are the risks to TXG?
The biggest overhang is demand: U.S. academic and NIH-linked research funding plus biopharma capital budgets have tightened sharply, and instrument sales dropped about 24% year over year, driving management's flat guidance. The company is still unprofitable on a net basis, so the valuation (price-to-sales near 7x) leans heavily on a growth reacceleration that may not arrive on schedule. Competition is intensifying from Illumina, Bruker Spatial, Bio-Techne, Akoya, Vizgen, Bio-Rad, and newer single-cell entrants, and 10x has a long history of patent litigation whose settlements produced non-recurring revenue that will not repeat. New-platform adoption (Atera) is unproven at scale, and results can be lumpy quarter to quarter.
How is TXG valued? (as of JULY 2026)
Snapshot for TXG as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$639M
- Q1 2026 revenue: ~$150.8M
- 2026 revenue guidance: ~$600M-$625M
- Gross margin: ~70%
- Cash & securities (no debt): ~$540M
- Market cap: ~$5B
10x Genomics trades at roughly 7x sales while revenue is essentially flat and the company still runs a small net loss, so the market is paying for future growth rather than current profits. The debt-free balance sheet with about $540M of cash gives it room to fund new launches. The key swing factor is whether academic and biopharma spending thaws enough to restart instrument placements.
How do you decide if TXG is a buy?
Rather than asking whether TXG is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold TXG indirectly through an index or sector ETF before adding more.
For the full picture, see the TXG stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about TXG against your real portfolio and see your actual exposure before deciding.
The bottom line on TXG
The bottom line: TXG's story right now is Consumables-led recurring revenue, with revenue (ttm) at ~$639M. If you believe that narrative continues, the call is about sizing TXG sensibly and checking overlap with what you own; if you doubt it (the risk: the biggest overhang is demand: U.S.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around TXG with Walnut
Use TXG as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is TXG a good stock to buy right now?
+
The case for TXG right now is Consumables-led recurring revenue, with revenue (ttm) at ~$639M. If you believe that thesis holds, TXG is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the biggest overhang is demand: U.S. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does TXG do?
+
10x Genomics, Inc.
What are the main risks of TXG?
+
The biggest overhang is demand: U.S. academic and NIH-linked research funding plus biopharma capital budgets have tightened sharply, and instrument sales dropped about 24% year over year, driving management's flat guidance. The company is still unprofitable on a net basis, so the valuation (price-to-sales near 7x) leans heavily on a growth reacceleration that may not arrive on schedule. Competition is intensifying from Illumina, Bruker Spatial, Bio-Techne, Akoya, Vizgen, Bio-Rad, and newer single-cell entrants, and 10x has a long history of patent litigation whose settlements produced non-recurring revenue that will not repeat. New-platform adoption (Atera) is unproven at scale, and results can be lumpy quarter to quarter.
What does TXG stand for and what does the company do?
+
TXG is the Nasdaq ticker for 10x Genomics, Inc. The company makes instruments, reagents, and software for single-cell and spatial biology, tools researchers use to measure gene activity in individual cells and map it across tissue. Its main products are Chromium, Visium, Xenium, and the new Atera platform.
Is 10x Genomics profitable?
+
Not yet on a net basis. In Q1 2026 the company reported a net loss of about $13.5M, though that narrowed sharply from the prior year. Gross margin improved to roughly 70% and operating expenses fell, so losses are shrinking even as revenue stays roughly flat.
How fast is 10x Genomics growing?
+
Slowly right now. Full-year 2026 guidance of about $600M to $625M implies only 0% to 4% growth after excluding one-time patent-settlement revenue. Consumables grew about 13% in Q1, but instrument sales fell around 24% as research budgets tightened, holding overall growth back.
Why has TXG revenue been flat?
+
A freeze in U.S. academic and NIH-linked research funding and cautious biopharma capital-equipment budgets have sharply reduced new instrument purchases. Because instruments seed future consumables demand, the funding slowdown weighs on both current and future revenue until spending recovers.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell TXG; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.